Sugi Predict

Sugi Predict / Targets / PLCD1

PLCD1

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 · P51178 · PLCD1 on Sugi Atlas →

2,088 patent compounds predicted against PLCD1, 1,793 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12675370 SCHEMBL12675370 0.67 1/20
SCHEMBL13497919 SCHEMBL13497919 0.67 1/20
SCHEMBL12339166 SCHEMBL12339166 0.66 1/20
SCHEMBL7516609 SCHEMBL7516609 0.65 1/20
SCHEMBL12764711 SCHEMBL12764711 0.64 1/20
SCHEMBL8508187 SCHEMBL8508187 0.63 1/20
SCHEMBL8532651 SCHEMBL8532651 0.62 1/20
SCHEMBL9586828 SCHEMBL9586828 0.62 1/20
SCHEMBL10140256 SCHEMBL10140256 0.62 1/20
SCHEMBL10140277 SCHEMBL10140277 0.62 1/20
Ethylenediamine Ethylenediamine (SCHEMBL565340) 0.61 1/20
SCHEMBL383254 SCHEMBL383254 0.61 1/20
SCHEMBL565248 SCHEMBL565248 0.61 1/20
SCHEMBL565479 SCHEMBL565479 0.61 1/20
SCHEMBL1270494 SCHEMBL1270494 0.61 1/20
SCHEMBL2153169 SCHEMBL2153169 0.61 1/20
SCHEMBL3143245 SCHEMBL3143245 0.61 1/20
SCHEMBL5841368 SCHEMBL5841368 0.61 1/20
SCHEMBL7849030 SCHEMBL7849030 0.61 1/20
SCHEMBL8407567 SCHEMBL8407567 0.61 1/20

Clinical trials — most relevant to PLCD1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Molecular Markers of Human Sperm Function nanWITHDRAWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity. nanUNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Clinical Characteristics of Primary Liver Cancer nanUNKNOWN
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Plaque Calcium Characterization and Ruptured Plaques nanUNKNOWN
Liver Cancer Prognosis Investigation Study nanNOT_YET_RECRUITING
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential nanNOT_YET_RECRUITING
The Dragon PLC Trial (DRAGON-PLC) nanRECRUITING
99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis nanCOMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) nanCOMPLETED
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome nanCOMPLETED
Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations nanWITHDRAWN
Study of Proteus Syndrome and Related Congenital Disorders nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PLCD1 binder may also engage these)

ProteinNameSimilarity
Q8R3B1 — 1.000 Q8R3B1 →
P10895 — 1.000 P10895 →
P10688 — 1.000 P10688 →
Q9BRC7 — 0.995 Q9BRC7 →
Q4R6L3 — 0.994 Q4R6L3 →
Q62711 — 0.993 Q62711 →
Q5RET0 — 0.993 Q5RET0 →
Q8SPR7 — 0.993 Q8SPR7 →
Q32NH8 — 0.992 Q32NH8 →
Q8K2J0 — 0.991 Q8K2J0 →
P21671 — 0.989 P21671 →
A5D6R3 — 0.988 A5D6R3 →
Q8K3R3 — 0.987 Q8K3R3 →
Q8N3E9 — 0.987 Q8N3E9 →
P51432 — 0.986 P51432 →
PLCB3 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 0.983 landscape →
Q00722 — 0.982 Q00722 →
O75038 — 0.982 O75038 →
Q5R4W6 — 0.981 Q5R4W6 →
Q62688 — 0.981 Q62688 →
Q9Z140 — 0.981 Q9Z140 →
A2AP18 — 0.980 A2AP18 →
Q99JE6 — 0.980 Q99JE6 →
O89040 — 0.980 O89040 →
Q3USB7 — 0.980 Q3USB7 →
TARS2 Threonine--tRNA ligase, mitochondrial 0.979 landscape →
Q8K394 — 0.979 Q8K394 →
Q15111 — 0.978 Q15111 →
Q4KWH8 — 0.978 Q4KWH8 →
Q2KHY1 — 0.978 Q2KHY1 →